National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Erenumab (Aimovig®)  is indicated for the treatment of chronic and episodic migraine in adults who have at least 4 migraine days per month when initiating treatment with erenumab.

NCPE Assessment Process Complete
Rapid review received 19/07/2018
Rapid review completed 15/08/2018
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of erenumab compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 28/08/2018
Pre-submission consultation with Applicant 24/09/2018
Submission received from Applicant 22/01/2019
Preliminary review sent to Applicant 01/04/2019
NCPE assessment re-commenced 01/05/2019
Factual accuracy sent to Applicant 31/07/2019
NCPE assessment re-commenced 06/08/2019
NCPE assessment completed 30/09/2019
NCPE assessment outcome Chronic Migraine: The NCPE recommends that erenumab be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments.*

Episodic Migraine: The NCPE recommends that erenumab not be considered for reimbursement.*




*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.